# RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

> **NCT06420973** · PHASE2 · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 54 (estimated)

## Conditions studied

- Ovarian Carcinoma
- Fallopian Tube Carcinoma
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** RC48+carboplatin±bevacizumab

## Key facts

- **NCT ID:** NCT06420973
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-16
- **Primary completion:** 2027-05-17
- **Final completion:** 2027-09-17
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06420973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06420973, "RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06420973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*